Dr. Michael Thiel published the second part of the three-part series on venture capital in the German life-science-industry. The article focuses on the role of life-science-corporate-venture-fonds for the innovation strategy of pharma and biotechnology companies. Moreover the motivation of corporate-venture-fonds for their investments and the differences in contrast to institutional venture-capital-fonds are discussed.

You can find the whole article here → (German-language link)